Novartis: OmalizumabAchieved all Targets in Phase III Safety Registration

Novartis: OmalizumabAchieved all Targets in Phase III Safety Registration

An announcement made by the Swiss drugmaker Novartis AG (NVS: Quote) on Wednesday suggested about the late-breaking results omalizumab clearing all the primary and secondary endpoints of a pivotal Phase III safety registration study in chronic spontaneous urticaria or CSU.

It is a chronic and debilitating form of hives with partial approved treatment options. GLACIAL is considered as the second of three pivotal Phase III studies. These studies conduct analysis about the efficacy and safety of omalizumab in CSU.

The result derived from the study supported supported the efficacy, safety and tolerability of omalizumab in patients with refractory CSU. It is a kind of chronic and debilitating skin disease with obstinate itch and hives.

Near about 40 percent of CSU patients were unsuccessful on ntihistamines. These include those who were taking the approved dose even for the fourth time. The doses, in terms of official regulations are currently available only for treatment for CSU.

However, Omalizumab is presently not at all approved or indicated for CSU. Supervision of the submissions for omalizumab in CSU is scheduled for later times in the current year. It is a collaborated effort of Novartis and Genentech, Inc.

The data was brought forward for the first time at the European Academy of Allergy and Clinical Immunology-World Allergy Organization World Allergy and Asthma Congress 2013 in Milan which is located in Italy.


FrenchTribune Specials

34,500 People are mentally unstable to own Guns in New York State

On Sunday, a news report found that about 34,500 people are listed as mentally unstable to have guns in New York State. This is under a law less than two-year-old that is one of the nation's toughest concerning mental health and firearms.

According to the New York Times' report based on records acquired by a Freedom of Information Law...

Most Popular

Sierra Nevada Corporation receives contract from US Department of Defense

The US Department of Defense (DOD) has given contract to...

Errors cost £2.5bn a year to NHS, says Health Secretary

Health Secretary Jeremy Hunt has said that errors in...

Medical experts find first case of addiction to Google Glass

Medical experts in the US have confirmed that they are...

40% Decline in Peru’s Glaciers over past four decades

A statement from Peru government on Wednesday said...

Poll

Can Greece Come out of Economic Problems: